EUDA Health Holdings Ltd (EUDA) Research & Development (2022 - 2023)
EUDA Health Holdings (EUDA) posted quarterly Research & Development of -$27299.0 for Q2 2023, down 109.66% year-over-year from $282708.0 in Q2 2022, and down 106.74% quarter-over-quarter from $404771.0 in Q1 2023.
EUDA Health Holdings Ltd (EUDA) Research & Development (2022 - 2023) Analysis & Trends
EUDA Health Holdings (EUDA) has reported Research & Development for 2 consecutive years, with -$27299.0 the latest figure, recorded in Q2 2023.
- In Q2 2023, Research & Development fell 109.66% year-over-year to -$27299.0; the TTM figure through Jun 2023 stood at $1.0 million (changed N/A YoY), while the FY2025 annual figure was $1.3 million, up 888.54% from the prior year.
- Research & Development retreated to -$27299.0 in Q2 2023 per EUDA's latest filing, from $404771.0 in the prior quarter.
- Across five years, Research & Development topped out at $404771.0 in Q1 2023 and bottomed at -$27299.0 in Q2 2023.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -27,299.00 |
| Mar 31, 2023 | 404,771.00 |
| Jun 30, 2022 | 282,708.00 |
| Mar 31, 2022 | 368,092.00 |